CellSource Co., Ltd. (TYO:4880)

Japan · Delayed Price · Currency is JPY

316.00

+8.00 (2.60%)

Aug 6, 2026, 12:32 PM JST

-53.46% (1Y)

Market Cap	6.11B -54.6%
Revenue (ttm)	3.67B -19.7%
Net Income	70.00M -91.4%
EPS	3.53 -91.5%
Shares Out	19.85M
PE Ratio	87.23
Forward PE	72.47
Dividend	5.00 (1.63%)
Ex-Dividend Date	Oct 30, 2025

Volume	17,500
Open	308.00
Previous Close	308.00
Day's Range	308.00 - 321.00
52-Week Range	294.00 - 709.00
Beta	-0.11
Analysts	n/a
Price Target	n/a
Earnings Date	Sep 8, 2026

About CellSource

CellSource Co., Ltd. engages in the regenerative medicine-related businesses in Japan. The company provides processing services to extract adipose-derived stem cells from patients’ adipose tissues, and to prepare platelet-rich plasma from patients’ blood; and offers support services for medical facilities providing regenerative medicine therapy. It is also involved in the sale of human stem cell-derived cosmetic ingredients; and Signalift series of anti-aging products, including a serum. The company was incorporated in 2015 and is headquartered... [Read more]

Industry Biotechnology

Sector Healthcare

Founded 2015

Employees 148

Stock Exchange Tokyo Stock Exchange

Ticker Symbol 4880

Full Company Profile

Financial Performance

In fiscal year 2025, CellSource's revenue was 3.71 billion, a decrease of -17.73% compared to the previous year's 4.51 billion. Earnings were 10.00 million, a decrease of -98.92%.

Financial Statements